vs

Side-by-side financial comparison of California Resources Corp (CRC) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

California Resources Corp is the larger business by last-quarter revenue ($119.0M vs $69.8M, roughly 1.7× RIGEL PHARMACEUTICALS INC). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs -46.3%).

California Resources Corporation is an American energy corporation engaged in hydrocarbon exploration in California. It is organized in Delaware and headquartered in Long Beach, California. Its mineral acreage holdings in California constitute the largest privately held position in the state.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

CRC vs RIGL — Head-to-Head

Bigger by revenue
CRC
CRC
1.7× larger
CRC
$119.0M
$69.8M
RIGL
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
-46.3%
CRC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CRC
CRC
RIGL
RIGL
Revenue
$119.0M
$69.8M
Net Profit
$268.1M
Gross Margin
91.5%
Operating Margin
-597.5%
33.2%
Net Margin
384.0%
Revenue YoY
21.2%
Net Profit YoY
1769.2%
EPS (diluted)
$-8.02
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRC
CRC
RIGL
RIGL
Q1 26
$119.0M
Q4 25
$679.0M
$69.8M
Q3 25
$715.0M
$69.5M
Q2 25
$702.0M
$101.7M
Q1 25
$814.0M
$53.3M
Q4 24
$826.0M
$57.6M
Q3 24
$870.0M
$55.3M
Q2 24
$412.0M
$36.8M
Net Profit
CRC
CRC
RIGL
RIGL
Q1 26
Q4 25
$12.0M
$268.1M
Q3 25
$64.0M
$27.9M
Q2 25
$172.0M
$59.6M
Q1 25
$115.0M
$11.4M
Q4 24
$33.0M
$14.3M
Q3 24
$345.0M
$12.4M
Q2 24
$8.0M
$-1.0M
Gross Margin
CRC
CRC
RIGL
RIGL
Q1 26
Q4 25
91.5%
Q3 25
93.2%
Q2 25
95.6%
Q1 25
91.7%
Q4 24
89.9%
Q3 24
85.5%
Q2 24
92.4%
Operating Margin
CRC
CRC
RIGL
RIGL
Q1 26
-597.5%
Q4 25
6.9%
33.2%
Q3 25
13.7%
40.9%
Q2 25
38.0%
60.1%
Q1 25
22.9%
23.9%
Q4 24
8.2%
28.9%
Q3 24
59.5%
25.4%
Q2 24
9.2%
1.2%
Net Margin
CRC
CRC
RIGL
RIGL
Q1 26
Q4 25
1.8%
384.0%
Q3 25
9.0%
40.2%
Q2 25
24.5%
58.6%
Q1 25
14.1%
21.5%
Q4 24
4.0%
24.9%
Q3 24
39.7%
22.5%
Q2 24
1.9%
-2.8%
EPS (diluted)
CRC
CRC
RIGL
RIGL
Q1 26
$-8.02
Q4 25
$0.21
$14.11
Q3 25
$0.76
$1.46
Q2 25
$1.92
$3.28
Q1 25
$1.26
$0.63
Q4 24
$0.87
$0.82
Q3 24
$3.78
$0.70
Q2 24
$0.11
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRC
CRC
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$155.0M
Total DebtLower is stronger
$52.5M
Stockholders' EquityBook value
$2.9B
$391.5M
Total Assets
$513.6M
Debt / EquityLower = less leverage
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRC
CRC
RIGL
RIGL
Q1 26
Q4 25
$132.0M
$155.0M
Q3 25
$196.0M
$137.1M
Q2 25
$72.0M
$108.4M
Q1 25
$214.0M
$77.1M
Q4 24
$372.0M
$77.3M
Q3 24
$241.0M
$61.1M
Q2 24
$1.0B
$49.1M
Total Debt
CRC
CRC
RIGL
RIGL
Q1 26
Q4 25
$52.5M
Q3 25
$1.0B
$60.0M
Q2 25
$1.0B
$60.0M
Q1 25
$1.0B
$60.0M
Q4 24
$1.1B
$60.0M
Q3 24
$1.1B
$60.0M
Q2 24
$1.2B
$60.0M
Stockholders' Equity
CRC
CRC
RIGL
RIGL
Q1 26
$2.9B
Q4 25
$3.7B
$391.5M
Q3 25
$3.4B
$117.6M
Q2 25
$3.4B
$81.9M
Q1 25
$3.5B
$18.6M
Q4 24
$3.5B
$3.3M
Q3 24
$3.5B
$-14.6M
Q2 24
$2.1B
$-29.9M
Total Assets
CRC
CRC
RIGL
RIGL
Q1 26
Q4 25
$7.4B
$513.6M
Q3 25
$6.8B
$242.5M
Q2 25
$6.7B
$206.7M
Q1 25
$6.8B
$176.0M
Q4 24
$7.1B
$164.0M
Q3 24
$7.1B
$139.4M
Q2 24
$4.5B
$128.4M
Debt / Equity
CRC
CRC
RIGL
RIGL
Q1 26
Q4 25
0.13×
Q3 25
0.29×
0.51×
Q2 25
0.30×
0.73×
Q1 25
0.29×
3.23×
Q4 24
0.32×
18.25×
Q3 24
0.32×
Q2 24
0.57×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRC
CRC
RIGL
RIGL
Operating Cash FlowLast quarter
$99.0M
$22.0M
Free Cash FlowOCF − Capex
$-32.0M
FCF MarginFCF / Revenue
-26.9%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters
$380.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRC
CRC
RIGL
RIGL
Q1 26
$99.0M
Q4 25
$235.0M
$22.0M
Q3 25
$279.0M
$24.0M
Q2 25
$165.0M
$30.5M
Q1 25
$186.0M
$-893.0K
Q4 24
$206.0M
$14.5M
Q3 24
$220.0M
$21.7M
Q2 24
$97.0M
$302.0K
Free Cash Flow
CRC
CRC
RIGL
RIGL
Q1 26
$-32.0M
Q4 25
$115.0M
Q3 25
$188.0M
Q2 25
$109.0M
Q1 25
$131.0M
Q4 24
$118.0M
Q3 24
$141.0M
Q2 24
$63.0M
FCF Margin
CRC
CRC
RIGL
RIGL
Q1 26
-26.9%
Q4 25
16.9%
Q3 25
26.3%
Q2 25
15.5%
Q1 25
16.1%
Q4 24
14.3%
Q3 24
16.2%
Q2 24
15.3%
Capex Intensity
CRC
CRC
RIGL
RIGL
Q1 26
Q4 25
17.7%
Q3 25
12.7%
Q2 25
8.0%
Q1 25
6.8%
Q4 24
10.7%
Q3 24
9.1%
Q2 24
8.3%
Cash Conversion
CRC
CRC
RIGL
RIGL
Q1 26
Q4 25
19.58×
0.08×
Q3 25
4.36×
0.86×
Q2 25
0.96×
0.51×
Q1 25
1.62×
-0.08×
Q4 24
6.24×
1.01×
Q3 24
0.64×
1.75×
Q2 24
12.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons